Edition:
United Kingdom

Zogenix Inc (ZGNX.OQ)

ZGNX.OQ on NASDAQ Stock Exchange Global Market

47.85USD
4:08pm BST
Change (% chg)

$-0.80 (-1.64%)
Prev Close
$48.65
Open
$48.45
Day's High
$49.45
Day's Low
$47.58
Volume
33,140
Avg. Vol
179,409
52-wk High
$62.75
52-wk Low
$11.85

Latest Key Developments (Source: Significant Developments)

Zogenix Announces Positive Top-Line Results From Second Pivotal Phase 3 Clinical Trial Of Zx008 In Dravet Syndrome
Thursday, 12 Jul 2018 

July 12 (Reuters) - Zogenix Inc ::ZOGENIX ANNOUNCES POSITIVE TOP-LINE RESULTS FROM SECOND PIVOTAL PHASE 3 CLINICAL TRIAL OF ZX008 IN DRAVET SYNDROME.ZOGENIX INC - ZX008 ALSO DEMONSTRATED STATISTICAL SIGNIFICANCE IN ALL KEY SECONDARY ENDPOINTS.ZOGENIX INC - U.S. AND EU REGULATORY SUBMISSIONS ON TRACK FOR Q4 OF 2018.ZOGENIX - PRIMARY ENDPOINT ACHIEVED - STATISTICALLY SIGNIFICANT CONVULSIVE SEIZURE REDUCTION FOR ZX008 VERSUS PLACEBO FOR ADJUNCTIVE TREATMENT OF SEIZURES.ZOGENIX INC - ZX008 ALSO DEMONSTRATED STATISTICALLY SIGNIFICANT IMPROVEMENT VERSUS PLACEBO IN BOTH KEY SECONDARY MEASURES.ZOGENIX - ZX008 GENERALLY WELL-TOLERATED IN STUDY WITH ADVERSE EVENTS CONSISTENT WITH THOSE OBSERVED IN STUDY 1 & KNOWN SAFETY PROFILE OF FENFLURAMINE.  Full Article

Zogenix Says Repaid Entire $20.1 Mln Of Outstanding Principal & Interest Under Its Loan And Security Agreement
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Zogenix Inc ::ZOGENIX SAYS REPAID IN FULL ENTIRE $20.1 MILLION OF OUTSTANDING PRINCIPAL & INTEREST UNDER ITS LOAN AND SECURITY AGREEMENT DATED AS OF DEC 30, 2014.ZOGENIX SAYS IN CONNECTION WITH REPAYMENT, CO WAS ALSO REQUIRED TO MAKE FINAL PAYMENT OF ABOUT $1.4 MILLION, OTHER PAYMENTS - SEC FILING.  Full Article

Zogenix Announces New Data From Pivotal Phase 3 Clinical Trial Of ZX008
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Zogenix Inc ::ZOGENIX ANNOUNCES NEW POSITIVE EFFICACY AND SAFETY DATA FROM PIVOTAL PHASE 3 CLINICAL TRIAL OF ZX008 IN DRAVET SYNDROME.ZOGENIX INC - DATA SHOWS ZX008 PATIENTS MORE LIKELY TO ACHIEVE CLINICALLY MEANINGFUL REDUCTION IN SEIZURE FREQUENCY COMPARED TO THOSE ON PLACEBO.ZOGENIX INC - LOOK FORWARD TO SHARING TOP-LINE RESULTS FROM SECOND PIVOTAL PHASE 3 TRIAL OF ZX008, STUDY 1504, IN Q2 OF 2018.  Full Article

Zogenix Announces Initiation Of Phase 3 Trial For ZX008 In Lennox-Gastaut Syndrome
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Zogenix Inc ::ZOGENIX ANNOUNCES INITIATION OF PHASE 3 TRIAL FOR ZX008 IN LENNOX-GASTAUT SYNDROME.  Full Article

Zogenix posts Q3 loss of $1.68 per share
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Zogenix Inc :Zogenix provides corporate update and reports third quarter 2017 financial results.Q3 earnings per share view $-0.93 -- Thomson Reuters I/B/E/S.Q3 loss per share $1.68.At September 30, 2017, company had cash and cash equivalents of $64.7 million, compared to $91.6 million at December 31, 2016​.  Full Article

Photo

Zogenix's seizure drug clears late-stage trial, shares soar

Zogenix Inc said on Thursday its drug to treat a rare form of childhood epilepsy reduced convulsive seizures in a second late-stage trial, sending the drug developer's shares up as much as 26 percent.